Chad Orevillo

Chad Orevillo currently serves as the Executive Vice President and Head of Development Operations at Inhibikase Therapeutics, Inc. since March 2025. Prior to this role, Chad held several high-level positions at Longboard Pharmaceuticals, including Executive Vice President and Vice President of Operations from October 2020 to March 2025, and at Arena Neuroscience, where Chad was Vice President and Head of Operations from April 2020 to March 2023. Chad's extensive experience includes leadership roles at Arena Pharmaceuticals, Pearl Therapeutics, Novartis, and Pharmacia, focusing on clinical development and operations across various therapeutic areas. Chad began working in the industry as a Medical Program Coordinator and Staff Immunologist at Merck from 1995 to 2000. Chad earned a Master of Public Health degree from Tulane University between 2003 and 2005.